

1 **Keeping up with the pathogens: Improved antimicrobial resistance detection and**
2 **prediction from *Pseudomonas aeruginosa* genomes**

3

4 Danielle E. Madden^{1,2}, Timothy Baird^{1,2,3}, Scott C. Bell^{4,5}, Kate L. McCarthy^{6,7}, Erin P. Price^{1,2*} and Derek
5 S. Sarovich^{1,2*#}

6

7 ¹Centre for Bioinnovation, University of the Sunshine Coast, Sippy Downs, Queensland, Australia

8 ²Sunshine Coast Health Institute, Birtinya, Queensland, Australia

9 ³Respiratory Department, Sunshine Coast University Hospital, Birtinya, Queensland, Australia

10 ⁴Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Chermside, Queensland, Australia

11 ⁵Children’s Health Research Centre, Faculty of Medicine, The University of Queensland, South
12 Brisbane, Queensland, Australia

13 ⁶University of Queensland Centre for Clinical Research, Herston, Queensland, Australia

14 ⁷Royal Brisbane and Women’s Hospital, Herston, Queensland, Australia

15

16 Keywords: Antibiotic, genomics, high-throughput sequencing, bioinformatics, AMR database,
17 metagenomics, whole-genome sequencing, AMR software, AMR prediction

18

19 Running title: AMR detection from *P. aeruginosa* genomes

20

21 #Corresponding author:

22 Derek S. Sarovich

23 dsarovich@usc.edu.au; +61 7 5456 3748

24 *Authors contributed equally

25 **Abstract**

26 **Background:** Antimicrobial resistance (AMR) is an intensifying threat that requires urgent mitigation to
27 avoid a post-antibiotic era. The ESKAPE pathogen, *Pseudomonas aeruginosa*, represents one of the
28 greatest AMR concerns due to increasing multi- and pan-drug resistance rates. Shotgun sequencing is
29 quickly gaining traction for *in silico* AMR profiling due to its unambiguity and transferability; however,
30 accurate and comprehensive AMR prediction from *P. aeruginosa* genomes remains an unsolved
31 problem.

32 **Methods:** We first curated the most comprehensive database yet of known *P. aeruginosa* AMR
33 variants. Next, we performed comparative genomics and microbial genome-wide association study
34 analysis across a Global isolate Dataset ($n=1877$) with paired antimicrobial phenotype and genomic
35 data to identify novel AMR variants. Finally, the performance of our *P. aeruginosa* AMR database,
36 implemented in our ARDaP software, was compared with three previously published *in silico* AMR
37 gene detection or phenotype prediction tools – abritAMR, AMRFinderPlus, ResFinder – across both the
38 Global Dataset and an analysis-naïve Validation Dataset ($n=102$).

39 **Results:** Our AMR database comprises 3639 mobile AMR genes and 733 AMR-conferring chromosomal
40 variants, including 75 chromosomal variants not previously reported, and 284 chromosomal variants
41 that we show are unlikely to confer AMR. Our pipeline achieved a genotype-phenotype balanced
42 accuracy (bACC) of 85% and 81% across 10 clinically relevant antibiotics when tested against the
43 Global and Validation Datasets, respectively, vs. just 56% and 54% with abritAMR, 58% and 54% with
44 AMRFinderPlus, and 60% and 53% with ResFinder.

45 **Conclusions:** Our ARDaP software and associated AMR variant database provides the most accurate
46 tool yet for predicting AMR phenotypes in *P. aeruginosa*, far surpassing the performance of current
47 tools. Implementation of our ARDaP-compatible database for routine AMR prediction from *P.*
48 *aeruginosa* genomes and metagenomes will improve AMR identification, addressing a critical facet in
49 combatting this treatment-refractory pathogen. However, knowledge gaps remain in our
50 understanding of the *P. aeruginosa* resistome, particularly the basis of colistin AMR.

51 **Background**

52 Antibiotic overuse and misuse [1] has driven the emergence of antimicrobial-resistant (AMR)
53 pathogens globally [2]. We are now on the verge of a ‘post-antibiotic era’, where simple infections
54 threaten to be untreatable with antimicrobials that once revolutionised modern medicine [3]. If
55 unmitigated, AMR infections are predicted to cause 10 million deaths globally by 2050 and cost
56 USD\$100 trillion per annum [4].

57 The ESKAPE pathogen, *Pseudomonas aeruginosa*, represents one of the biggest AMR threats due to its
58 intrinsic resistance towards many antibiotics, environmental ubiquity, ability to infect a wide spectrum
59 of hosts, and high global mortality rate [5-7]. Accurately detecting and predicting AMR phenotype
60 from genotype in *P. aeruginosa* has proven challenging [8], even using machine learning approaches
61 [9], with some approaches as accurate as a coin flip [8]. A major shortcoming of current *in silico* AMR
62 tools is that they largely focus on detecting AMR gene gain [10, 11] and a small number of
63 chromosomally encoded single-nucleotide polymorphisms (SNPs) [12-14]. However, *P. aeruginosa* can
64 also evolve AMR through chromosomal insertions-deletions (indels), loss-of-function mutations (e.g.
65 large deletions or frameshift mutations), structural variants, and copy-number variations (CNVs) [15].
66 Despite recent advances [11, 12], most AMR tools remain limited in their scope and accuracy [16] – for
67 example, loss-of-function mutations, a major contributor to AMR, are largely ignored [14], AMR
68 databases are often not species-specific [14, 17], they do not resolve to the individual antibiotic level
69 [11], and precursor mutations conferring reduced antimicrobial susceptibility are overlooked. These
70 limitations are especially problematic for accurate AMR detection and prediction in pathogens
71 encoding complex resistomes like *P. aeruginosa* [8].

72 To address this gap, we curated and validated the most comprehensive *P. aeruginosa*-specific AMR
73 variant database yet, which, when used in conjunction with the Antimicrobial Resistance Detection
74 and Prediction (ARDaP) software [14], enables high-accuracy AMR prediction from *P. aeruginosa*
75 genomes. Performance of our ARDaP-compatible AMR variant database was first assessed across 1877
76 diverse *P. aeruginosa* strains (“Global Dataset”), and subsequently, across 102 analysis-naïve *P.*

77 *aeruginosa* strains (“Validation Dataset”). Our approach, which we demonstrate far exceeds the
78 performance to current AMR prediction software, provides a crucial steppingstone towards the
79 routine clinical use of genomics and metagenomics to inform personalised *P. aeruginosa* antimicrobial
80 treatment regimens.

81 **Methods**

82 ***P. aeruginosa* AMR variant database construction.** To cover the spectrum of AMR variants found in *P.*
83 *aeruginosa*, an ARDaP v1.9 [14] compatible SQLite database was populated with all known AMR
84 variants described in this pathogen to date
85 (https://github.com/dsarov/ARDaP/blob/master/Databases/Pseudomonas_aeruginosa_pao1/). Gene
86 names, locus tags, and genomic coordinates in our AMR variant database were based on PAO1
87 (NC_002516.2) [18]. An exhaustive literature search was conducted to encompass biomedical
88 literature published from 1980 to April 20th 2023 within the MEDLINE database. Search terms included
89 “antimicrobial resistance” and “*P. aeruginosa*” accompanied by a variable search term for targeted
90 literature, and included either: i) antibiotic class (e.g. carbapenem, aminoglycoside); ii) AMR
91 mechanism (e.g. efflux, gene expression enzymatic inactivation); or iii) a known AMR gene (e.g. *oprD*,
92 *ampC*, *gyrA*).

93 The resultant *P. aeruginosa* AMR database (Dataset 1) consists of three tables. The first table, ‘1.
94 Antibiotics’, lists the ten clinically relevant antibiotics that were interrogated in our study: amikacin,
95 cefepime, ceftazidime, ciprofloxacin, colistin, imipenem, meropenem, piperacillin,
96 piperacillin/tazobactam, and tobramycin, whether these drugs are first-line, second-line or tertiary,
97 and their associated antibiotic class. The second (‘2. Variants_SNP_indel’) and third (‘3. Coverage’)
98 tables list the entire *P. aeruginosa* mutational resistome [19, 20], which includes all known genetic
99 alterations that can lead to AMR, including the functional loss of chromosomal genes (under, ‘3.
100 Coverage’). These databases include all AMR variants and genes that: i) cause efflux pump
101 upregulation [21]; ii) alter outer membrane permeability [22]; iii) de-repress or alter the substrate
102 range of the AmpC cephalosporinase [23]; and/or iv) alter the antimicrobial target [24]. AMR gene
103 acquisition was interrogated with ResFinder v4.0 [25], using default parameters and retaining only
104 genes identified at 100% similarity and with 100% coverage. Resfinder is integrated within the ARDaP
105 tool and run as part of the default pipeline. The default ResFinder database was manually curated to:
106 1) remove false-positive hits that were consistently identified in AMR sensitive strains; *bla*_{OXA}-

107 395_1_AY306133, *bla*_{OXA-396_1_AY306134}, *bla*_{PAO_4_AY083592}, *bla*_{PAO_1_AY083595}, *bla*_{PAO_3_FJ666073}, *bla*_{PAO_2_FJ666065}, and
108 *crpP*_{HM560971}; 2) include additional gene variants identified within the Global Dataset in
109 aminoglycoside AMR-conferring genes *aac*(6')-Ib, *aac*(6')-IIa, *aac*(6')-Ib-cr, and *aac*(3)-IIIa; and 3) as per
110 ResFinder recommendations for *P. aeruginosa*, the substrate range for *bla*_{OXA-2_1_DQ112222} and *bla*_{OXA-}
111 *2_2_GQ466184* was expanded to include meropenem and imipenem.

112 For the aminoglycosides (i.e. amikacin and tobramycin), known AMR variants consisted of point
113 mutations in *algA* [26], *amgS* [27], *fusA1* [26, 28-33], *rplB* [34], *ptsP* [33, 35], and *tuf1* [26], and loss-of-
114 function mutations in the *nuo* [36-38] pathway. For the carbapenems (i.e. imipenem and meropenem),
115 cephalosporins (i.e. ceftazidime), and β -lactams with or without an inhibitor (i.e. piperacillin and
116 piperacillin/tazobactam), mutations that alter or expand the substrate range of the *ampC*
117 cephalosporinase [23, 39-42] or that alter *ampC* expression, including inactivation of penicillin-
118 binding-protein 4 (PBP4; *dacB*) [43-45], *ampD* [45-47], *ampDh2* [47], *ampDh3* [47], *ampE* [47], *ampR*
119 [48, 49], *mpl* [50], or *ampC-ampR* intergenic region [51], mutations in PBP3 (*ftsI*) [48, 52, 53], and
120 mutations that cause *oprD* loss, inactivation, or down-regulation [49, 54-60], were included. For
121 ciprofloxacin AMR prediction, we included point mutations in *gyrA* [61-67], *gyrB* [62, 63, 65, 68], *parC*
122 [61-63, 66], and *parE* [62, 63, 65]. For colistin AMR prediction, point mutations in *cprS* [52], *pmrA* [69],
123 *pmrB* [31, 69-74], *phoP* [69], and *phoQ* [69] were included.

124 Efflux pumps play a key role in AMR development in *P. aeruginosa*, predominantly through regulator
125 alterations, which drive efflux pump overexpression [15]. To predict MexAB-OprM upregulation, which
126 is associated with β -lactam (including carbapenem) AMR [21], we included mutations in the *cis* (*mexR*
127 [29, 61, 64, 75, 76]) and *trans* (*nalC* [77, 78] and *nalD* [23, 71, 77-79]) regulators of this efflux pump.
128 For MexCD-OprJ upregulation, which is associated with fluoroquinolone and specific β -lactam AMR
129 [21], mutations and loss-of coverage in the single known regulator, *nfxB* [61, 64] were included. For
130 MexEF-OprN upregulation, which is linked to fluoroquinolone AMR [21], we included function-altering
131 mutations or loss of coverage in *mexS* [80], the LysR family regulator *mexT* [81], and the global
132 regulator *mvaT* [82]. For MexXY upregulation, which is associated with aminoglycoside and

133 fluoroquinolone AMR, we included loss-of-coverage in two refined regions of *mexZ* [83, 84] and the
134 intergenic region (*mexOZ*) between *mexZ* and *mexX* [85, 86]. Additionally, functional gene loss variants
135 across the entire *P. aeruginosa* chromosome, identified via transposon insertion experiments [36, 38,
136 87], were included.

137 In addition to variants that confer AMR, mutations in essential AMR-conferring genes that cause
138 unusual antimicrobial susceptibility were included: efflux pumps *mexAB* [88, 89], *mexXY* [90], *mexCD*
139 [91] and *mexEF* [82, 92], and the *ampC* regulators *ampP* and *ampG*, which are required for high-level
140 *ampC* expression [51]. We also included additional targets for (meta)genome quality control and *P.*
141 *aeruginosa* speciation (*ecfX* [93]), and genes responsible for conferring a hypermutator phenotype
142 (*mutS*, *mutL* and *uvrD* [94]).

143 **Global Dataset.** To comprehensively capture geographic, genomic, and phenotypic diversity, we
144 collated a large and comprehensive *P. aeruginosa* isolate collection ($n=1877$) of all publicly available
145 strains with paired antimicrobial phenotype and genomic data [9, 20, 32, 54, 95-103] (Dataset 2, Table
146 S1). This dataset includes many antimicrobial-susceptible strains, which are essential for developing
147 and refining high-quality AMR databases [14, 104]. Isolates with minimum inhibitory concentration
148 (MIC) data were reclassified as sensitive, intermediate, or resistant using the CLSI M100S-Ed32:2022
149 guidelines.

150 **Validation Dataset.** To independently evaluate AMR software performance, we examined 102
151 phylogenetically diverse, analysis-naïve, clinical *P. aeruginosa* strains (Figures S1 and S2). Isolates were
152 obtained from people admitted to hospitals in Qld, Australia, with cystic fibrosis (CF; $n=42$),
153 bacteraemia ($n=35$), chronic obstructive pulmonary disease (COPD; $n=21$), bronchiectasis ($n=1$), ear
154 infection ($n=1$), ulcer ($n=1$), or urinary tract infection ($n=1$), between 2008 and 2020 (Table S2). Eighty-
155 four isolates have previously been genome-sequenced (NCBI BioProject PRJNA761496; GenBank
156 accessions NSXK00000000.1 and NSZK00000000.1) and some have previously undergone antimicrobial
157 susceptibility testing [105, 106]. For the current study, 18 additional COPD isolates (SCHI0038.S.1,
158 SCHI0050.S.3, SCHI0058.S.1, SCHI0058.S.2, SCHI0059.S.1, SCHI0064.S.1, SCHI0065.S.1, SCHI0068.S.3,

159 SCHI0070.S.1, SCHI0070.S.1, SCHI0084.S.1, SCHI0098.S.1, SCHI0103.S.1, SCHI0107.S.1, SCHI0109.S.1,
160 SCHI0109.S.2, SCHI0112.S.1, SCHI0112.S.2) were sequenced and appended to BioProject
161 PRJNA761496. Antimicrobial susceptibility profiles for 8 of 10 clinically-relevant antibiotics were
162 determined across the Validation Dataset (Table S2) using disc diffusions, following CLSI M100S-
163 Ed32:2022 guidelines. Meropenem and ciprofloxacin MICs were determined by ETEST (bioMérieux,
164 Murarrie, Australia) using sensitive, intermediate, and resistant MIC cut-offs of ≤ 4 , 8, and ≥ 16 $\mu\text{g/mL}$
165 for meropenem, and ≤ 0.5 , 1, and ≥ 2 $\mu\text{g/mL}$ for ciprofloxacin. PAO1 (Belgian Coordinated Collection of
166 Microorganisms [BCCM], Ghent University, Belgium) and LMG 6395 (BCCM) were included as
167 antimicrobial-susceptible controls.

168 **Microbial genome-wide association study (mGWAS) and machine learning (ML) for AMR prediction.**

169 To identify novel AMR variants, mGWAS [107] was performed on the Global *P. aeruginosa* Dataset
170 ($n=1877$ strains), with SNPs and indels identified using SPANDx v4.0.1 [108]. To increase the signal-to-
171 noise ratio, variants found in antimicrobial-sensitive isolates were penalised four-fold compared with
172 AMR strains due to a presumed large effect size [109]. The top 50 variants associated with each AMR
173 phenotype were assessed for their ability to improve phenotype prediction; those that improved
174 phenotype prediction were included in the AMR database. Additionally, a supervised ML approach was
175 performed using the Global Dataset and the AMR database as features for model creation.

176 **Comparative genomic analysis.** To identify additional novel AMR variants, we conducted a
177 comparative genomic analysis using SPANDx, with a focus on AMR strains that did not encode a known
178 AMR variant (i.e. false negatives). These strains were compared to their closest antimicrobial-sensitive
179 relative(s) as determined by the whole-genome phylogenetic analysis (**Figure S1**). SNPs and indels that
180 separated AMR from antimicrobial-sensitive strain/s were identified, annotated and investigated with
181 manual inspection to prioritise mutations in known AMR genes. Candidate variants were then tested
182 against the Global Dataset to determine whether they improved phenotype prediction. AMR variants
183 that increased balanced accuracy (bACC) were included in the database; those that did not alter, or
184 that decreased bACC, were discarded.

185 **AMR prediction analysis.** AMR prediction was performed using our *P. aeruginosa* AMR database
186 (v1.0), implemented in ARDaP [110]. ARDaP was chosen as it is the only AMR software that can detect
187 all mutation types (i.e. SNPs, indels, gene gain, gene loss, frameshift mutations, structural variants,
188 and CNVs) [14]. ARDaP also has a built-in feature that automatically generates a clinician-friendly
189 antimicrobial susceptibility summary report for each strain (Figure S3) to simplify *in silico* AMR
190 interpretation [14]. ARDaP performance was compared against four tools for AMR phenotype
191 prediction and/or AMR variant identification: abritAMR [111], RGI v5.1.0 and CARD v3.0.9 [11],
192 ResFinder v4.1 [10], and AMRFinderPlus v3.8.28 [112]. As abritAMR and AMRFinderPlus frequently
193 report predicted AMR phenotypes to the antibiotic class level only, we chose to interpret AMR variant
194 presence for a given class as conferring AMR towards all antibiotics within that class. Importantly,
195 AMRFinderPlus is not intended for clinical phenotype prediction
196 (<https://github.com/ncbi/amr/wiki/Interpreting-results#genotype-vs-phenotype>) but has been
197 included as a benchmark for gene detection accuracy. For the purposes of software comparisons, gene
198 identification by AMRFinderPlus was interpreted as conferring phenotypic resistance.

199 A variant scoring scheme has previously been described by Cortes-Lara and colleagues, which
200 employed a 0 (no effect) through 1 (EUCAST AMR) scale to predict *in silico* AMR profiles [102]. We
201 expanded upon this scheme by providing an automated weighted score for all AMR variants in our
202 database that quantifies their contribution, positive or negative, towards AMR development (Dataset
203 1, 'Threshold' column); this score is recorded for each antibiotic on ARDaP's automatically generated
204 clinician-friendly report (Figure S3), unlike the Cortes-Lara scheme, which requires manual scoring for
205 each antibiotic and strain [102]. Using our scoring system, variants known to cause AMR in isolation
206 score as 100%, whereas AMR variants known to confer AMR in a stepwise manner (that is, only when
207 in combination with other variant/s), or that only result in intermediate resistance, are given a lower
208 score (e.g. 40-50%). This method accounts for both the additive nature of chromosomal mutations in
209 *P. aeruginosa*, and for the decreased AMR potential caused by loss of efflux pumps or essential

210 transcriptional regulators. Acquired AMR genes identified by Resfinder within ARDaP were considered
211 to confer full AMR, i.e. are scored at 100% for the purposes of phenotype prediction.

212 **Intermediate resistance prediction.** The capacity of our AMR variant database to predict intermediate
213 resistance phenotypes was examined against the Global Dataset using the following criteria:

- 214 • A true-positive prediction occurred when either: i) an AMR strain was classed as AMR, or ii) an
215 intermediate strain was identified as intermediate;
- 216 • A true-negative prediction occurred when an antimicrobial-sensitive strain was identified as
217 antimicrobial sensitive;
- 218 • A false-positive prediction occurred when either: i) an antimicrobial-sensitive strain was
219 classed as intermediate or AMR, or ii) an intermediate strain was classed as AMR; and
- 220 • A false-negative prediction occurred when either: i) an intermediate strain was classed as
221 antimicrobial-sensitive, or when an AMR strain was predicted to be antimicrobial-sensitive or
222 intermediate.

223 These rules provided the strictest evaluation criteria for the assessment of ARDaP's ability to identify
224 intermediate strains. Only ARDaP's intermediate resistance prediction performance was assessed as
225 abritAMR, AMRFinderPlus, CARD, and ResFinder all lack the capacity to identify intermediate
226 resistance.

227 **AMR software predictive performance in *P. aeruginosa*.** Due to its inability to predict AMR towards
228 individual antibiotics, and a very high rate of false-positive predictions in the Global Dataset, CARD was
229 deemed unsuitable for *P. aeruginosa* AMR analysis and was excluded from further assessment. For all
230 other tools, predictive performance was determined using bACC [113, 114], which averages sensitivity
231 [i.e. true positives/(true positives + false negatives)], and specificity [i.e. true negatives/(true negatives
232 + false positives)]. This metric was chosen as it accounts for dataset imbalance; that is, it minimises
233 over- or under- representation of antimicrobial-sensitive or AMR strains that may otherwise make
234 certain tools appear better or worse due to inherent dataset bias [8]. Additionally, we compared recall

235 (AMR) [true positives/(true positives + false negatives), precision (AMR) or positive predictive value
236 (PPV) [true positives/(true positives + false positives), recall (sensitivity) [true negatives/(true
237 negatives + false positives) and precision (sensitivity) or negative predictive value (NPV) [true
238 negatives/(true negatives + false negatives)] across all software tools.

239 **Results**

240 ***P. aeruginosa* AMR variant identification and refinement.** An extensive literature search was
241 undertaken to identify all known and putative chromosomal variants that lead to AMR in *P.*
242 *aeruginosa*. Among the 733 identified chromosomal AMR variants, 284 putative variants were
243 classified as ‘natural variation’ as they were common in both antimicrobial-sensitive and AMR strains
244 in our Global Dataset, and therefore deemed unlikely to contribute to an AMR phenotype. Most of
245 these naturally occurring variants had been previously reported as putatively causing AMR, with little
246 to no functional investigation. Importantly, no functionally validated AMR driving variants were re-
247 classified as ‘natural variation’. Next, using mGWAS and comparative genomic analyses of the Global
248 Dataset, we identified 75 previously unreported AMR variants associated with one or more AMR
249 phenotypes (Table 2). In total, we identified 736 chromosomal variants in known AMR loci (Dataset 2),
250 of which 374 were associated with AMR and 284 were natural variation.

251 **Predictive performance across Global Dataset.** Although superior to CARD, abritAMR, AMRFinderPlus,
252 and ResFinder still showed relatively poor bACCs for most antibiotics, with average bACCs of between
253 56 and 60%, well below ARDaP’s average bACC of 85% (Figure 1A).

254 The best abritAMR, AMRFinderPlus, and ResFinder predictions were achieved for the aminoglycosides,
255 with average bACCs of 75%, 75%, and 82%, respectively, although these rates were lower than
256 ARDaP’s average aminoglycoside bACC of 92%. abritAMR, AMRFinderPlus, and ResFinder AMR
257 prediction for all other antibiotics showed poor to very poor bACCs. AMRFinderPlus had a bACC of just
258 50% for the penicillins, cephalosporins, and colistin – the same predictive capacity as a coin flip – and
259 had only a slightly better bACC for ciprofloxacin (58%), imipenem (58%), and meropenem (61%).

260 ResFinder also had a bACC of just 50% for cephalosporins and colistin, and performed worse for
261 carbapenems (average bACC of 50%) than AMRFinderPlus, although it was better for penicillins
262 (average bACC of 62%) and ciprofloxacin (bACC of 62%). abritAMR was the worst at predicting
263 penicillin phenotypes, with an average bACC of just 43%, worse than a coin flip; its performance was
264 otherwise identical to AMRFinderPlus. In contrast, ARDaP surpassed abritAMR, AMRFinderPlus, and
265 ResFinder across all 10 antibiotics, with bACCs ranging from 60% (colistin) to 94% (tobramycin) (Figure
266 1A).

267 **Predictive performance across Validation Dataset.** We next tested abritAMR, AMRFinderPlus, ARDaP,
268 and ResFinder across the Validation Dataset of 102 Australian clinical *P. aeruginosa* strains (Table S2)
269 to determine each software's performance in an analysis-naïve dataset. As no strains in the Validation
270 Dataset displayed colistin AMR, the bACC for this antibiotic could not be assessed. These strains
271 otherwise exhibited similar AMR rates to the Global Dataset, ranging from 26% for meropenem to 58%
272 for piperacillin (Table S4).

273 Overall, ARDaP had high predictive accuracy (average bACC of 81%) across all antibiotics (Figure 1B),
274 vastly outperforming ResFinder (average bACC of 53%), abritAMR, and AMRFinderPlus (average bACC
275 of 54% each). Notably, the ResFinder meropenem bACC, at just 43%, yielded worse performance than
276 a coin flip.

277 **Inclusion of the novel AMR variants identified in the Global Dataset.** The inclusion of these markers
278 increased Validation Dataset sensitivity by an average of 4% (range 0 to 27%) depending on antibiotic,
279 with the sensitivity of most antibiotics (meropenem, imipenem, ciprofloxacin, cefepime, and
280 piperacillin/tazobactam) remaining unchanged. Amikacin increased the most (27%) due to the
281 inclusion of a SNP in *rpIB* (Gly138Ser), followed by tobramycin at 4%, and piperacillin and ceftazidime
282 at 3% each."

283 **ARDaP performance between the Global and Validation Datasets.** Whilst ARDaP bACC between the
284 datasets were broadly similar, there was a greater proportion of false-positive and false-negative

285 variants encoding AMR towards piperacillin (32% difference), tobramycin (24% difference), cefepime
286 (19% difference), amikacin (12% difference), and meropenem (9% difference) in the Validation
287 Dataset. In contrast, there was a greater proportion of false-positive and false-negative variants
288 encoding amikacin AMR (5% difference) in the Global Dataset (Figure 1).

289 Comparative genomic analysis of Validation Dataset isolates that yielded false-negative
290 aminoglycoside AMR predictions identified that many belonged to a single multilocus sequence type
291 (ST), ST801, also known as AUST-06. Among 23/24 aminoglycoside-AMR ST801 isolates, a clade-
292 specific missense variant in elongation factor G (FusA1 S459F) was identified; this SNP was not
293 observed in other Global or Validation Dataset isolates. The remaining aminoglycoside-AMR ST801
294 strain, SCH10010.S.1, encoded AAC(6')-IIa, an aminoglycoside-modifying enzyme. Inclusion of FusA1
295 S459F into our AMR database significantly increased ARDaP bACCs for the Validation Dataset by an
296 average 19% for both amikacin and tobramycin, raising them to 95% and 90%, respectively, with no
297 impact on Global Dataset bACC.

298 **Precision and recall among AMR software.** ARDaP demonstrated excellent precision and recall for
299 predicting antimicrobial-sensitive and AMR phenotypes, ranging from 73% (average AMR recall) to
300 96% (average sensitivity recall) (Figure 2A). In contrast, abritAMR ranged from 54% (average AMR
301 precision) to 62% (average sensitivity precision) (Figure 2B), AMRFinderPlus ranged from 54% (average
302 AMR precision) to 62% (average AMR recall) (Figure 2C), and ResFinder ranged from only 42% (average
303 AMR precision) to 68% (average sensitivity precision) (Figure 2D).

304 For colistin, abritAMR, AMRFinderPlus, and ResFinder all yielded AMR precision and recall values of
305 0%; in other words, none of these tools identified colistin AMR variants in strains exhibiting a colistin
306 AMR phenotype. In comparison, ARDaP identified colistin AMR strains with 21% recall and 100%
307 precision. Similarly, abritAMR, AMRFinderPlus, and ResFinder all failed to predict cefepime sensitivity
308 in any cefepime-sensitive strain (Figures 2B-2D), instead erroneously classing every strain as cefepime-
309 resistant, whereas ARDaP correctly identified cefepime-sensitive strains with 96% precision and 96%

310 recall (Figure 2A). All three tools also failed to predict ceftazidime sensitivity. In addition, abritAMR
311 and AMRFinderPlus failed to identify piperacillin sensitivity in any of the tested strains, and
312 AMRFinderPlus yielded failed to identify piperacillin/tazobactam sensitivity (Figures 2B and 2C).

313 **Predictive performance for intermediate resistance.** The inclusion of isolates with intermediate
314 resistance reduced ARDaP bACCs by between 1 to 13% (6% average), depending on the antibiotic
315 (Table S5). Intermediate resistance inclusion was most detrimental to cefepime AMR prediction (-
316 13%), followed by imipenem (-8%), meropenem, ciprofloxacin and ceftazidime (-7%),
317 piperacillin/tazobactam and amikacin (-5%), piperacillin (-4%) and tobramycin (-1%). Colistin prediction
318 was unchanged as no intermediate category exists for this antibiotic.

319 Discussion

320 The increasing role of high-throughput sequencing in the clinic has driven the concomitant
321 development of bioinformatic tools for AMR variant detection and antimicrobial phenotype prediction
322 [115]. However, current gold standard AMR tools are limited in their accuracy and performance due to
323 their heavy focus on AMR gene gain rather than AMR-conferring chromosomal variants, and their
324 inability to detect the gamut of genetic mutations that can confer AMR (i.e. gene loss, indels, CNVs,
325 and structural variants) [14]. In addition, most tools have primarily focused on detection of AMR genes
326 rather than AMR phenotype prediction. These shortcomings become acutely evident when attempting
327 to predict AMR in pathogens with complex resistomes like *P. aeruginosa* [8].

328 To address this issue, we first constructed a comprehensive and accurate database of AMR variants
329 encoded by *P. aeruginosa*. Our database of 733 chromosomal AMR-conferring variants (Dataset 2)
330 comprises 374 previously identified AMR variants that we confirmed were significantly associated with
331 an AMR phenotype, along with 75 AMR variants identified in this study. A further 284 AMR variants
332 identified by us, and others, were classed as natural variants due to their non-significant association
333 with AMR strains (Table S3). These variants were included for two reasons: i) to allow ARDaP's
334 coverage algorithm to scan known AMR genes for novel, high-consequence mutations (e.g. frameshift
335 mutations in *oprD* that lead to carbapenem AMR) while avoiding natural variation that does not
336 impact function, ii) to substantially reduce the legwork involved in identifying putative novel AMR
337 variants using mGWAS or comparative genomics, and iii) to reduce the over-reporting of natural
338 variants as putatively AMR conferring. Our natural variant list also provides a valuable resource for
339 minimising erroneous AMR variant reporting in future *P. aeruginosa* AMR variant discovery studies.

340 Next, performance assessment of our ARDaP-compatible AMR database against the Global and
341 Validation Datasets showed that our tool outstripped the predictive performance of current 'gold
342 standard' AMR software across all 10 antibiotics, yielding average bACC of 85%, vs. just 56%, 58% and
343 60% for abriTAMR, AMRFinderPlus and ResFinder, respectively (Figure 1). This performance difference
344 is due to our chromosomal AMR variant database, which directly links genotypes with individual

345 antibiotic phenotypes, and provides weighted scores on variant contribution towards AMR
346 development (Dataset 1). Our findings concur with a recent study of 654 *P. aeruginosa* genomes,
347 which also found that CARD and ResFinder exhibited poor AMR prediction performance metrics across
348 all 11 tested anti-pseudomonal antibiotics [8].

349 Although still inferior to ARDaP, abritAMR, AMRFinderPlus, and ResFinder performed best when
350 predicting aminoglycoside phenotypes in the Global Dataset (Figure 1A), which is heavily populated
351 with American and European strains (Table S1). These tools performed substantially worse when
352 tested against the Australian Validation Dataset (Figure 1B), with the average aminoglycoside bACC
353 dropping by 16% for AMRFinderPlus and 26% for ResFinder. ARDaP's bACC also initially dropped by
354 18% for the aminoglycosides. Upon closer inspection, we found that this performance reduction was
355 predominantly due to false-negative calls among the ST801 isolates, a geographically restricted clone
356 that has only been reported in people with CF in Qld, Australia [116]. Inclusion of one novel *fusA1*
357 variant identified with comparative genomics in our AMR variant database restored ARDaP's
358 performance to bACC of 90% and 95% for amikacin and tobramycin, respectively. This performance
359 difference across isolate datasets can be attributed to two phenomena. The first is the predominance
360 of aminoglycoside-modifying enzymes in the Global (33%) but not Validation (8%) Datasets, reflecting
361 potential major differences in the geographic prevalence of these enzymes that requires further
362 exploration. The second is the enrichment of CF-derived isolates in the Validation Dataset, which
363 comprise 86% of the aminoglycoside AMR strains (Figure S1). These isolates have largely developed
364 aminoglycoside AMR via chromosomal mutation rather than aminoglycoside-modifying enzyme
365 acquisition; as such, abritAMR, AMRFinderPlus, and ResFinder exhibited poor aminoglycoside AMR
366 predictive capacity due to their limited chromosomal AMR variant databases. These performance
367 differences highlight the need for including isolates from diverse sources, disease states, and locales to
368 provide the most relevant AMR prediction software benchmarking comparisons. Our results suggest
369 that abritAMR, AMRFinderPlus, and ResFinder are not useful for predicting aminoglycoside AMR from

370 CF-derived *P. aeruginosa*, particularly in the Australian context, although this finding requires further
371 exploration across larger, geographically diverse datasets.

372 Our findings revealed important weaknesses in abritAMR, AMRFinderPlus, and ResFinder when used
373 for phenotype prediction. All three tools yielded bACCs of just 50% for cephalosporin prediction,
374 abritAMR and AMRFinderPlus yielded a bACC of just 50% for piperacillin (Figures 1A and 1B), and
375 abritAMR performed worse than a coin flip for predicting piperacillin/tazobactam phenotypes, with a
376 bACC of just 35%. These cases of under-performance were largely attributed to sensitive isolates being
377 predicted as AMR (Figure 2). The inferior performance of abritAMR and AMRFinderPlus over ResFinder
378 was further exacerbated by their software design; for most anti-pseudomonal antibiotics, these tools
379 only predict phenotypes to the antibiotic class level. To facilitate direct software comparisons, AMR
380 identified for a given antibiotic class by abritAMR and AMRFinderPlus was extrapolated to all
381 antibiotics within that class, which likely led to higher imprecision or error due to differences in within-
382 class antibiotic spectrum of activity. For instance, the poor abritAMR piperacillin/tazobactam bACC
383 may be attributed to this tool only reporting ‘ β -lactamase’ presence; however, the impact of this β -
384 lactamase on piperacillin/tazobactam efficacy is not explicitly reported due to insufficient granularity.

385 Based on our and other’s [8] collective findings, we strongly discourage the use of abritAMR,
386 AMRFinderPlus, or ResFinder for *in silico* cephalosporin AMR prediction in *P. aeruginosa* as none of
387 these tools are currently capable of accurately differentiating sensitive from AMR strains for these
388 antibiotics. Further, abritAMR and AMRFinderPlus should not be used to predict penicillin
389 susceptibility phenotypes in *P. aeruginosa* due to their insufficient resolution.

390 Colistin prediction proved the most challenging of the 10 tested antibiotics, yielding bACCs of 50%
391 with abriTAMR, AMRFinderPlus, and ResFinder, and 60% with ARDaP. ARDaP the only tool able to
392 correctly predict some colistin AMR strains; the other three tools erroneously classified all *P.*
393 *aeruginosa* strains as colistin-sensitive (Figures 2B and 2C). Accurate colistin prediction may have been
394 hampered by the purported unreliability of gradient diffusion methods (e.g. disc diffusions, ETESTS) to
395 accurately measure colistin breakpoints due to poor antibiotic diffusion and Mueller-Hinton agar

396 manufacturer differences [117, 118]. Our study has identified a major gap in understanding the basis
397 of colistin AMR, and underscores the need for much more work in this area, especially given the
398 increasing use of inhaled colistin in treatment-refractory, multidrug-resistant *P. aeruginosa* infections
399 [119, 120].

400 Loss-of-function mutations affecting the specialised porin, OprD, are the most common cause of
401 carbapenem AMR in *P. aeruginosa*, particularly in clinical isolates [9]. Although *oprD* is notoriously
402 hypervariable [121], ARDaP's ability to accurately identify functional OprD loss accounted for its high
403 carbapenem predictive accuracy (average bACC of 89% vs. just 61% for AMRFinderPlus and 52% for
404 ResFinder). This outcome highlights the complex nature of the *P. aeruginosa* resistome, the necessity
405 of AMR variant curation efforts, the value of AMR prediction tools that can accurately detect the
406 spectrum of chromosomal variants, and the value of species-specific AMR variant databases to achieve
407 the most accurate AMR predictions.

408 Mutations leading to chromosomal cephalosporinase (*ampC*) overexpression are an important cause
409 of β -lactam AMR [15, 122]. To predict *ampC* upregulation, our database includes function-altering
410 mutations in genes known to directly or indirectly regulate *ampC*. These chromosomally-encoded
411 variants, alongside acquired cephalosporinases, accounted for the high average ARDaP bACC observed
412 for the cephalosporins (84% vs. just 50% with abritAMR, AMRFinderPlus, and ResFinder; Figure 1). The
413 prominence of *ampC* over-expression-associated determinants provides further support that this
414 mechanism is a major cause of acquired cephalosporin AMR, particularly in clinical *P. aeruginosa*
415 isolates [122, 123]. In support of this hypothesis, Khaledi and colleagues demonstrated a considerably
416 higher bACC for ceftazidime AMR prediction when using both transcriptomic and genomic data (82%)
417 compared with just genomic data (67%) [9]. Genomics alone cannot currently identify all instances of
418 *ampC* over-expression, either because up-regulation is the result of an epigenic change, or the
419 mutation remains cryptic due to an incomplete understanding of *ampC* regulatory mechanisms.
420 Indeed, a review of intrinsic β -lactamases by Juan and colleagues details the complexity of *ampC*
421 expression and its intricate regulation, along with the challenge of corresponding elevated β -

422 lactamase MICs driven by *ampC* upregulation to clinical AMR breakpoints [124]. Using a combination
423 of genomic and transcriptomic data will likely lead to further improvements in AMR prediction for
424 most antibiotics [9, 122].

425 Predicting intermediate resistance is exceedingly difficult from genomic data alone, even with complex
426 machine learning algorithms that combine transcriptomic and genomic data [9]. We also encountered
427 difficulties in predicting intermediate resistance, with the inclusion of intermediate strains dropping
428 bACCs by up to 13% (Table S5). Possible explanations include the need to understand the contribution
429 of stepwise variants in conferring decreased antibiotic susceptibility [15, 67, 125], subtle and rapidly
430 reversible gene expression alterations [9] caused by methylation [126] or dynamic environmental
431 stimuli, and undetected strain mixtures. Further refinement of our ARDaP-compatible database, such
432 as capacity to analyse RNA-seq data, will continue to improve this critical yet understudied area.

433 Nevertheless, the pioneering capacity of ARDaP to predict intermediate resistance, including stepwise
434 mutations that lower the barrier to full AMR development, and to differentiate strain mixtures in
435 metagenomic data, has important implications for detecting emerging AMR in *P. aeruginosa* and
436 informing earlier treatment shifts [14].

437 Errors introduced during sample collection, metadata curation, specimen processing, or sequencing
438 may be partially responsible for our inability to predict AMR with a 100% bACC for any antibiotic. For
439 example, 11 strains in the Khaledi *et al.* dataset [9] possessed variants known to confer ceftazidime
440 AMR (e.g. *bla*_{VIM-[2,4,47]}, *bla*_{OXA-2}, *bla*_{GES-[1,5]}) yet were reported as ceftazidime-sensitive, and 22 strains in
441 the Kos *et al.* dataset were amikacin-sensitive, yet possessed the aminoglycoside-modifying enzyme
442 gene *aac(6')-Ib-cr*, known to cause amikacin AMR and reduced ciprofloxacin susceptibility [127]. Due
443 to the presence of these known AMR variants, all tools identified these strains as AMR, contributing to
444 imperfect bACC (Figure 1) and poor precision (Figure 2) for amikacin and ceftazidime. As we did not
445 have access to these strains, it was not possible to retest their AMR phenotypes or to repeat genome
446 sequencing; however, we hypothesise that these strains would generate different results upon
447 phenotypic retesting or re-sequencing. Alternatively, these AMR variants may be present but

448 functionally or transcriptionally inactive, resulting in false-positive predictions for these isolates that
449 must be factored into future AMR prediction estimates.

450 We recognise several study limitations. First, some false-positive predictions were identified across all
451 antibiotic classes with our ARDaP-compatible database; however, these rates were significantly lower
452 than those reported by other software (Figure 1). Whilst not ideal, we chose to retain a small number
453 of AMR variants that result in low-frequency false-positive predictions as: i) some strains may have
454 reverted to a sensitive phenotype, despite encoding a known AMR variant; and ii) we included
455 phenotypic data generated by others, which may harbour inaccuracies. Functional profiling will be
456 essential to fully understand the contribution of each of these variants in conferring AMR. Second,
457 although we aimed for a phylogenetically diverse Validation Dataset (Figure S1, S2), only isolates from
458 Queensland, Australia, were included in this dataset, limiting geographic and genetic representation.
459 Despite this shortcoming, the Validation Dataset proved extremely useful for identifying AMR variant
460 database deficits across all three AMR tools, particularly those variants encoding AMR towards the
461 aminoglycosides, piperacillin, cefepime, and meropenem, highlighting clear areas of need for future
462 research efforts. Third, due to cost constraints, we only performed ciprofloxacin and meropenem
463 ETESTs for the Validation Dataset isolates, with disc diffusions used for the remaining eight antibiotics,
464 a less robust methodology that may have led to some minor discrepancies in antimicrobial phenotype
465 assignments. Fourth, we did not test out ARDaP's capacity to identify *P. aeruginosa* AMR variants from
466 simulated and real metagenomic datasets and strain mixtures for this study as we have proven this
467 capacity elsewhere [14, 106] nor were we able to compare software performance against ARESdb
468 [128] due to the proprietary nature of this database. Finally, our study would have benefitted from the
469 inclusion of transcriptomic data [9] to identify additional novel variants associated with AMR. Although
470 our understanding of the molecular mechanisms of AMR in *P. aeruginosa* is improving rapidly in the
471 genomics era, false-negative predictions still occur across all antibiotic classes. Using ARDaP, such
472 false-negative strains can now be rapidly identified and targeted for future functional work to pinpoint
473 novel AMR variants and mechanisms.

474 **Declarations**

475 **Ethics approval and consent to participate.** Clinical specimen collection was approved by The Prince
476 Charles Hospital (HREC/13/QPCH/127 and HREC/2019/QPCH/48013) and Royal Brisbane and Women's
477 Hospital (DA: jl) Human Research Ethics Committees. Participants with CF or COPD provided written
478 consent; a waiver of informed consent was approved for other specimens due to a low-to-negligible
479 risk assessment.

480 **Consent for publication.** Not applicable.

481 **Availability of data and materials.** The datasets supporting the conclusions of this article are available
482 in the NCBI GenBank (references NSXK000000000.1 and NSZK000000000.1) and Sequence Read Archive
483 database via BioProject accession PRJNA761496 (Validation Dataset), and BioProject accessions
484 PRJEB15036, PRJEB21341, PRJEB29539, PRJEB14771, PRJNA297679, PRJNA317143, PRJNA526797,
485 PRJNA264310, PRJNA388357, PRJNA793523, PRJEB40140 and PRJNA532924 (Global Dataset). The *P.*
486 *aeruginosa* AMR database constructed for this study is freely available at:
487 https://github.com/dsarov/ARDaP/tree/master/Databases/Pseudomonas_aeruginosa_pao1. The
488 ARDaP software is freely available at: <https://github.com/dsarov/ARDaP>. All code used in this
489 manuscript is available at https://github.com/dsarov/P_aeruginosa_ARDaP_manuscript.

490 **Competing interests.** The authors declare that they have no competing interests.

491 **Funding.** This work was supported by Advance Queensland [AQIRF0362018 to D.S.S., AQRF13016-
492 17RD2 to E.P.P.]; the Wishlist Sunshine Coast Health Foundation [2019-14 to T.B., E.P.P., D.S.S.]; and
493 the National Health and Medical Research Council [GNT455919 to S.C.B.]. The funders had no role in
494 study design, data acquisition, analysis, interpretation, writing, or manuscript submission.

495 **Authors' contributions.** DEM drafted the initial manuscript, compiled the original *P. aeruginosa* AMR
496 variant database, performed data analyses and laboratory work, and assisted with ARDaP software
497 refinement; TB provided chronic obstructive pulmonary disease respiratory specimens that were used
498 to retrieve *P. aeruginosa* isolates, assisted with obtaining ethics approvals for sputum and bronchial

499 washing collection, and obtained study funding; SCB provided CF sputa that were used to retrieve *P.*
500 *aeruginosa* isolates, and obtained ethics approval for sputum collection; KM provided bloodstream *P.*
501 *aeruginosa* isolates, and obtained ethics approval for blood collection; EPP assisted with study
502 conception, obtaining and overseeing ethics approvals, manuscript preparation, data analyses and
503 laboratory work, provided student supervision, obtained study funding, and assisted with curation of
504 the natural variant database; and DSS conceived and led the study, wrote the ARDaP software, refined
505 the *P. aeruginosa* AMR variant database, assisted with manuscript preparation, data analyses and
506 laboratory work, provided student supervision, and obtained study funding. All authors read and
507 approved of the final manuscript.

508 **Acknowledgements.** We wish to thank Jane Neill (Sunshine Coast Hospital and Health Service,
509 Sunshine Coast University Hospital) for providing the chronic obstructive pulmonary samples used in
510 this study, and Kay Ramsay (University of Queensland) and Tamieka Fraser (University of the Sunshine
511 Coast) for laboratory support.

512 References

- 513 1. Mancuso G, Midiri A, Gerace E, Biondo C: **Bacterial antibiotic resistance: The most critical**
514 **pathogens.** *Pathogens (Basel, Switzerland)* 2021, **10**(10):1310.
- 515 2. Bassetti M, Merelli M, Temperoni C, Astilean A: **New antibiotics for bad bugs: where are we?**
516 *Annals of Clinical Microbiology and Antimicrobials* 2013, **12**(1):22.
- 517 3. Alanis AJ: **Resistance to antibiotics: are we in the post-antibiotic era?** *Archives of Medical*
518 *Research* 2005, **36**(6):697-705.
- 519 4. **Antimicrobial resistance: Tackling a crisis for the health and wealth of nations**
- 520 5. G. B. D. Antimicrobial Resistance Collaborators: **Global mortality associated with 33 bacterial**
521 **pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.** *Lancet*
522 2022, **400**(10369):2221-2248.
- 523 6. Denissen J, Reyneke B, Waso-Reyneke M, Havenga B, Barnard T, Khan S, Khan W: **Prevalence**
524 **of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired**
525 **infection and risk to human health.** *Int J Hyg Environ Health* 2022, **244**:114006.
- 526 7. Haenni M, Hocquet D, Ponsin C, Cholley P, Guyeux C, Madec JY, Bertrand X: **Population**
527 **structure and antimicrobial susceptibility of *Pseudomonas aeruginosa* from animal**
528 **infections in France.** *BMC Vet Res* 2015, **11**:9.
- 529 8. Mahfouz N, Ferreira I, Beisken S, von Haeseler A, Posch AE: **Large-scale assessment of**
530 **antimicrobial resistance marker databases for genetic phenotype prediction: a systematic**
531 **review.** *Journal of Antimicrobial Chemotherapy* 2020, **75**(11):3099-3108.
- 532 9. Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo TH, Oliver A, Cabot G, Kola A, Gastmeier
533 P, Hogardt M *et al*: **Predicting antimicrobial resistance in *Pseudomonas aeruginosa* with**
534 **machine learning-enabled molecular diagnostics.** *EMBO Mol Med* 2020, **12**(3):e10264.
- 535 10. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
536 Rebelo AR, Florensa AF *et al*: **ResFinder 4.0 for predictions of phenotypes from genotypes.**
537 *Journal of Antimicrobial Chemotherapy* 2020, **75**(12):3491-3500.
- 538 11. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen A-
539 LV, Cheng AA, Liu S *et al*: **CARD 2020: antibiotic resistome surveillance with the**
540 **comprehensive antibiotic resistance database.** *Nucleic Acids Research* 2019, **48**(D1):D517-
541 D525.
- 542 12. Hunt M, Mather AE, Sanchez-Buso L, Page AJ, Parkhill J, Keane JA, Harris SR: **ARIBA: Rapid**
543 **antimicrobial resistance genotyping directly from sequencing reads.** *Microbial genomics*
544 2017, **3**(10):e000131.
- 545 13. Zankari E, Allesoe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM: **PointFinder: A novel web**
546 **tool for WGS-based detection of antimicrobial resistance associated with chromosomal**
547 **point mutations in bacterial pathogens.** *Journal of Antimicrobial Chemotherapy* 2017,
548 **72**(10):2764-2768.
- 549 14. Madden DE, Webb JR, Steinig EJ, Currie BJ, Price EP, Sarovich DS: **Taking the next-gen step:**
550 **Comprehensive antimicrobial resistance detection from *Burkholderia pseudomallei*.**
551 *EBioMedicine* 2021, **63**:103152.
- 552 15. Lister PD, Wolter DJ, Hanson ND: **Antibacterial-resistant *Pseudomonas aeruginosa*: Clinical**
553 **impact and complex regulation of chromosomally encoded resistance mechanisms.** *Clinical*
554 *Microbiology Reviews* 2009, **22**(4):582-610.
- 555 16. Pesesky MW, Hussain T, Wallace M, Patel S, Andleeb S, Burnham CD, Dantas G: **Evaluation of**
556 **machine learning and rules-based approaches for predicting antimicrobial resistance profiles**
557 **in Gram-negative Bacilli from whole genome sequence data.** *Frontiers in microbiology* 2016,
558 **7**:1887.
- 559 17. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM: **ARG-**
560 **ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial**
561 **genomes.** *Antimicrobial agents and chemotherapy* 2014, **58**(1):212-220.

- 562 18. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warren P, Hickey MJ, Brinkman FS, Hufnagle
563 WO, Kowalik DJ, Lagrou M *et al*: **Complete genome sequence of *Pseudomonas aeruginosa***
564 **PAO1, an opportunistic pathogen.** *Nature* 2000, **406**(6799):959-964.
- 565 19. Lopez-Causape C, Cabot G, Del Barrio-Tofino E, Oliver A: **The versatile mutational resistome of**
566 ***Pseudomonas aeruginosa*.** *Frontiers in microbiology* 2018, **9**:685.
- 567 20. Kos VN, Deraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA, Corbeil J, Gardner H: **The**
568 **resistome of *Pseudomonas aeruginosa* in relationship to phenotypic susceptibility.**
569 *Antimicrobial agents and chemotherapy* 2015, **59**(1):427-436.
- 570 21. Poole K: ***Pseudomonas aeruginosa*: Resistance to the max.** *Frontiers in microbiology* 2011,
571 **2**:65-65.
- 572 22. Richardot C, Plesiat P, Fournier D, Monlezun L, Broutin I, Llanes C: **Carbapenem resistance in**
573 **cystic fibrosis strains of *Pseudomonas aeruginosa* as a result of amino acid substitutions in**
574 **porin OprD.** *International journal of antimicrobial agents* 2015, **45**(5):529-532.
- 575 23. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N:
576 **Efflux pumps, OprD porin, AmpC beta-lactamase, and multiresistance in *Pseudomonas***
577 ***aeruginosa* isolates from cystic fibrosis patients.** *Antimicrobial agents and chemotherapy*
578 2010, **54**(5):2219-2224.
- 579 24. Lister PD, Wolter DJ, Hanson ND: **Antibacterial-resistant *Pseudomonas aeruginosa*: Clinical**
580 **impact and complex regulation of chromosomally encoded resistance mechanisms.** *Clinical*
581 *Microbiology Reviews* 2009, **22**(4):582-610.
- 582 25. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
583 Rebelo AR, Florensa AF *et al*: **ResFinder 4.0 for predictions of phenotypes from genotypes.** *J*
584 *Antimicrob Chemother* 2020, **75**(12):3491-3500.
- 585 26. Heffernan AJ, Sime FB, Sarovich DS, Neely M, Guerra-Valero Y, Naicker S, Cottrell K, Harris P,
586 Andrews KT, Ellwood D *et al*: **Pharmacodynamic evaluation of plasma and epithelial lining**
587 **fluid exposures of amikacin against *Pseudomonas aeruginosa* in a dynamic *in vitro* hollow-**
588 **fiber infection model.** *Antimicrobial agents and chemotherapy* 2020, **64**(9).
- 589 27. Lau CH, Krahn T, Gilmour C, Mullen E, Poole K: **AmgRS-mediated envelope stress-inducible**
590 **expression of the *mexXY* multidrug efflux operon of *Pseudomonas aeruginosa*.**
591 *MicrobiologyOpen* 2015, **4**(1):121-135.
- 592 28. Bolard A, Plésiat P, Jeannot K: **Mutations in gene *fusA1* as a novel mechanism of**
593 **aminoglycoside resistance in clinical strains of *Pseudomonas aeruginosa*.** *Antimicrobial*
594 *agents and chemotherapy* 2018, **62**(2).
- 595 29. Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL: **A large-scale whole-**
596 **genome comparison shows that experimental evolution in response to antibiotics predicts**
597 **changes in naturally evolved clinical *Pseudomonas aeruginosa*.** *Antimicrobial agents and*
598 *chemotherapy* 2019.
- 599 30. López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA, Johansen HK, Figuerola J,
600 Cantón R, Kidd TJ, Molin S *et al*: **Evolution of the *Pseudomonas aeruginosa* mutational**
601 **resistome in an international cystic fibrosis clone.** *Sci Rep* 2017, **7**(1):5555.
- 602 31. Lopez-Causape C, Rubio R, Cabot G, Oliver A: **Evolution of the *Pseudomonas aeruginosa***
603 **aminoglycoside mutational resistome *in vitro* and in the cystic fibrosis setting.** *Antimicrobial*
604 *agents and chemotherapy* 2018, **62**(4).
- 605 32. Sherrard LJ, Tai AS, Wee BA, Ramsay KA, Kidd TJ, Ben Zakour NL, Whiley DM, Beatson SA, Bell
606 SC: **Within-host whole genome analysis of an antibiotic resistant *Pseudomonas aeruginosa***
607 **strain sub-type in cystic fibrosis.** *PLoS One* 2017, **12**(3):e0172179.
- 608 33. Feng Y, Jonker MJ, Moustakas I, Brul S, Ter Kuile BH: **Dynamics of mutations during**
609 **development of resistance by *Pseudomonas aeruginosa* against five antibiotics.**
610 *Antimicrobial agents and chemotherapy* 2016, **60**(7):4229-4236.
- 611 34. Khaledi A, Weimann A, Schniederjans M, Asgari E, Kuo T-H, Oliver A, Cabot G, Kola A,
612 Gastmeier P, Hogardt M *et al*: **Predicting antimicrobial resistance in *Pseudomonas***
613 ***aeruginosa* with machine learning-enabled molecular diagnostics.** *EMBO molecular medicine*
614 2020, **12**(3):e10264-e10264.

- 615 35. Sanz-Garcia F, Hernando-Amado S, Martinez JL: **Mutational evolution of *Pseudomonas***
616 ***aeruginosa* resistance to ribosome-targeting antibiotics.** *Front Genet* 2018, **9**:451.
- 617 36. Schurek KN, Marr AK, Taylor PK, Wiegand I, Semene L, Khaira BK, Hancock RE: **Novel genetic**
618 **determinants of low-level aminoglycoside resistance in *Pseudomonas aeruginosa*.**
619 *Antimicrobial agents and chemotherapy* 2008, **52**(12):4213-4219.
- 620 37. Sun E, Gill EE, Falsafi R, Yeung A, Liu S, Hancock REW: **Broad-spectrum adaptive antibiotic**
621 **resistance associated with *Pseudomonas aeruginosa* mucin-dependent surfing motility.**
622 *Antimicrobial agents and chemotherapy* 2018, **62**(9).
- 623 38. Dotsch A, Becker T, Pommerenke C, Magnowska Z, Jansch L, Haussler S: **Genomewide**
624 **identification of genetic determinants of antimicrobial drug resistance in *Pseudomonas***
625 ***aeruginosa*.** *Antimicrobial agents and chemotherapy* 2009, **53**(6):2522-2531.
- 626 39. Berrazeg M, Jeannot K, Ntsogo Enguene VY, Broutin I, Loeffert S, Fournier D, Plesiat P:
627 **Mutations in beta-Lactamase *ampC* increase resistance of *Pseudomonas aeruginosa* isolates**
628 **to antipseudomonal cephalosporins.** *Antimicrobial agents and chemotherapy* 2015,
629 **59**(10):6248-6255.
- 630 40. Colque CA, Albarracín Orio AG, Feliziani S, Marvig RL, Tobares AR, Johansen HK, Molin S,
631 Smania AM: **Hypermutator *Pseudomonas aeruginosa* exploits multiple genetic pathways to**
632 **develop multidrug resistance during long-term infections in the airways of cystic fibrosis**
633 **patients.** *Antimicrobial agents and chemotherapy* 2020, **64**(5).
- 634 41. Slater CL, Winogrodzki J, Fraile-Ribot PA, Oliver A, Khajehpour M, Mark BL: **Adding insult to**
635 **injury: Mechanistic basis for how AmpC mutations allow *Pseudomonas aeruginosa* to**
636 **accelerate cephalosporin hydrolysis and evade avibactam.** *Antimicrobial agents and*
637 *chemotherapy* 2020, **64**(9).
- 638 42. Fernandez-Esgueva M, Lopez-Calleja AI, Mulet X, Fraile-Ribot PA, Cabot G, Huarte R, Rezusta A,
639 Oliver A: **Characterization of AmpC beta-lactamase mutations of extensively drug-resistant**
640 ***Pseudomonas aeruginosa* isolates that develop resistance to ceftolozane/tazobactam during**
641 **therapy.** *Enferm Infecc Microbiol Clin (Engl Ed)* 2020, **38**(10):474-478.
- 642 43. Moya B, Dotsch A, Juan C, Blazquez J, Zamorano L, Haussler S, Oliver A: **Beta-lactam resistance**
643 **response triggered by inactivation of a nonessential penicillin-binding protein.** *PLoS Pathog*
644 2009, **5**(3):e1000353.
- 645 44. Zamorano L, Reeve TM, Deng L, Juan C, Moya B, Cabot G, Voadlo DJ, Mark BL, Oliver A: **NagZ**
646 **inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4**
647 **mutations, in *Pseudomonas aeruginosa*.** *Antimicrobial agents and chemotherapy* 2010,
648 **54**(9):3557-3563.
- 649 45. Barbosa C, Gregg KS, Woods RJ: **Variants in *ampD* and *dacB* lead to *in vivo* resistance**
650 **evolution of *Pseudomonas aeruginosa* within the central nervous system.** *Journal of*
651 *Antimicrobial Chemotherapy* 2020, **75**(11):3405-3408.
- 652 46. Langaee TY, Gagnon L, Huletsky A: **Inactivation of the *ampD* gene in *Pseudomonas***
653 ***aeruginosa* leads to moderate-basal-level and hyperinducible AmpC beta-lactamase**
654 **expression.** *Antimicrobial agents and chemotherapy* 2000, **44**(3):583-589.
- 655 47. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, Oliver A: **Molecular mechanisms of beta-**
656 **lactam resistance mediated by AmpC hyperproduction in *Pseudomonas aeruginosa* clinical**
657 **strains.** *Antimicrobial agents and chemotherapy* 2005, **49**(11):4733-4738.
- 658 48. Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, Hoiby N: **Constitutive high expression of**
659 **chromosomal beta-lactamase in *Pseudomonas aeruginosa* caused by a new insertion**
660 **sequence (IS1669) located in *ampD*.** *Antimicrobial agents and chemotherapy* 2002,
661 **46**(11):3406-3411.
- 662 49. Quale J, Bratu S, Gupta J, Landman D: **Interplay of efflux system, *ampC*, and *oprD* expression**
663 **in carbapenem resistance of *Pseudomonas aeruginosa* clinical isolates.** *Antimicrobial agents*
664 *and chemotherapy* 2006, **50**(5):1633-1641.
- 665 50. Tsutsumi Y, Tomita H, Tanimoto K: **Identification of novel genes responsible for**
666 **overexpression of *ampC* in *Pseudomonas aeruginosa* PAO1.** *Antimicrobial agents and*
667 *chemotherapy* 2013, **57**(12):5987-5993.

- 668 51. Kong KF, Aguila A, Schneper L, Mathee K: ***Pseudomonas aeruginosa* β -lactamase induction**
669 **requires two permeases, AmpG and AmpP.** *BMC microbiology* 2010, **10**:328.
- 670 52. Cabot G, Lopez-Causape C, Ocampo-Sosa AA, Sommer LM, Dominguez MA, Zamorano L, Juan
671 C, Tubau F, Rodriguez C, Moya B *et al*: **Deciphering the resistome of the widespread**
672 ***Pseudomonas aeruginosa* sequence type 175 international high-risk clone through whole-**
673 **genome sequencing.** *Antimicrob Agents Chemother* 2016, **60**(12):7415-7423.
- 674 53. Clark ST, Sinha U, Zhang Y, Wang PW, Donaldson SL, Coburn B, Waters VJ, Yau YCW, Tullis DE,
675 Guttman DS *et al*: **Penicillin-binding protein 3 is a common adaptive target among**
676 ***Pseudomonas aeruginosa* isolates from adult cystic fibrosis patients treated with beta-**
677 **lactams.** *International journal of antimicrobial agents* 2019, **53**(5):620-628.
- 678 54. Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM,
679 Sorlí L, Tubau F, Gómez-Zorrilla S *et al*: **Genomics and susceptibility profiles of extensively**
680 **drug-resistant *Pseudomonas aeruginosa* isolates from Spain.** *Antimicrobial agents and*
681 *chemotherapy* 2017, **61**(11).
- 682 55. Sherrard LJ, Wee BA, Duplancic C, Ramsay KA, Dave KA, Ballard E, Wainwright CE, Grimwood K,
683 Sidjabat HE, Whiley DM *et al*: **Emergence and impact of *oprD* mutations in *Pseudomonas***
684 ***aeruginosa* strains in cystic fibrosis.** *Journal of cystic fibrosis: official journal of the European*
685 *Cystic Fibrosis Society* 2021.
- 686 56. Livermore DM: **Interplay of impermeability and chromosomal beta-lactamase activity in**
687 **imipenem-resistant *Pseudomonas aeruginosa*.** *Antimicrobial agents and chemotherapy* 1992,
688 **36**(9):2046-2048.
- 689 57. Ocampo-Sosa AA, Cabot G, Rodriguez C, Roman E, Tubau F, Macia MD, Moya B, Zamorano L,
690 Suarez C, Pena C *et al*: **Alterations of *OprD* in carbapenem-intermediate and -susceptible**
691 **strains of *Pseudomonas aeruginosa* isolated from patients with bacteremia in a Spanish**
692 **multicenter study.** *Antimicrobial agents and chemotherapy* 2012, **56**(4):1703-1713.
- 693 58. Fraile-Ribot PA, Mulet X, Cabot G, Del Barrio-Tofiño E, Juan C, Perez JL, Oliver A: ***In vivo***
694 **emergence of resistance to novel cephalosporin-beta-lactamase inhibitor combinations**
695 **through the duplication of amino acid D149 from OXA-2 beta-lactamase (OXA-539) in**
696 **sequence type 235 *Pseudomonas aeruginosa*.** *Antimicrobial agents and chemotherapy* 2017,
697 **61**(9).
- 698 59. Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Häussler S, Oliver A:
699 ***Pseudomonas aeruginosa* ceftolozane-tazobactam resistance development requires multiple**
700 **mutations leading to overexpression and structural modification of AmpC.** *Antimicrobial*
701 *agents and chemotherapy* 2014, **58**(6):3091-3099.
- 702 60. Perron K, Caille O, Rossier C, Van Delden C, Dumas JL, Kohler T: ***CzcR-CzcS*, a two-component**
703 **system involved in heavy metal and carbapenem resistance in *Pseudomonas aeruginosa*.** *J*
704 *Biol Chem* 2004, **279**(10):8761-8768.
- 705 61. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ: **Mutations in *GyrA*, *ParC*, *MexR* and**
706 ***NfxB* in clinical isolates of *Pseudomonas aeruginosa*.** *International journal of antimicrobial*
707 *agents* 2003, **21**(5):409-413.
- 708 62. Lee JK, Lee YS, Park YK, Kim BS: **Alterations in the *GyrA* and *GyrB* subunits of topoisomerase II**
709 **and the *ParC* and *ParE* subunits of topoisomerase IV in ciprofloxacin-resistant clinical**
710 **isolates of *Pseudomonas aeruginosa*.** *International journal of antimicrobial agents* 2005,
711 **25**(4):290-295.
- 712 63. Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S: **Quantitative contributions of target**
713 **alteration and decreased drug accumulation to *Pseudomonas aeruginosa* fluoroquinolone**
714 **resistance.** *Antimicrobial agents and chemotherapy* 2013, **57**(3):1361-1368.
- 715 64. Jalal S, Wretling B: **Mechanisms of quinolone resistance in clinical strains of *Pseudomonas***
716 ***aeruginosa*.** *Microbial drug resistance (Larchmont, NY)* 1998, **4**(4):257-261.
- 717 65. Alyaseen SA, Piper KE, Rouse MS, Steckelberg JM, Patel R: **Selection of cross-resistance**
718 **following exposure of *Pseudomonas aeruginosa* clinical isolates to ciprofloxacin or cefepime.**
719 *Antimicrobial agents and chemotherapy* 2005, **49**(6):2543-2545.

- 720 66. Akasaka T, Tanaka M, Yamaguchi A, Sato K: **Type II topoisomerase mutations in**
721 **fluoroquinolone-resistant clinical strains of *Pseudomonas aeruginosa* isolated in 1998 and**
722 **1999: role of target enzyme in mechanism of fluoroquinolone resistance.** *Antimicrobial*
723 *agents and chemotherapy* 2001, **45**(8):2263-2268.
- 724 67. Rehman A, Jeukens J, Levesque RC, Lamont IL: **Gene-gene interactions dictate ciprofloxacin**
725 **resistance in *Pseudomonas aeruginosa* and facilitate prediction of resistance phenotype**
726 **from genome sequence data.** *Antimicrobial agents and chemotherapy* 2021, **65**(7):e0269620.
- 727 68. Chilam J, Argimon S, Limas MT, Masim ML, Gayeta JM, Lagrada ML, Olorosa AM, Cohen V,
728 Hernandez LT, Jeffrey B *et al*: **Genomic surveillance of *Pseudomonas aeruginosa* in the**
729 **Philippines, 2013-2014.** *Western Pac Surveill Response J* 2021, **12**(2):4-18.
- 730 69. Lee JY, Ko KS: **Mutations and expression of PmrAB and PhoPQ related with colistin resistance**
731 **in *Pseudomonas aeruginosa* clinical isolates.** *Diagn Microbiol Infect Dis* 2014, **78**(3):271-276.
- 732 70. Moskowitz SM, Ernst RK, Miller SI: **PmrAB, a two-component regulatory system of**
733 ***Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and**
734 **addition of aminoarabinose to lipid A.** *J Bacteriol* 2004, **186**(2):575-579.
- 735 71. Abraham N, Kwon DH: **A single amino acid substitution in PmrB is associated with polymyxin**
736 **B resistance in clinical isolate of *Pseudomonas aeruginosa*.** *FEMS Microbiol Lett* 2009,
737 **298**(2):249-254.
- 738 72. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI,
739 Denton M, Conway SP *et al*: **PmrB mutations promote polymyxin resistance of *Pseudomonas***
740 ***aeruginosa* isolated from colistin-treated cystic fibrosis patients.** *Antimicrobial agents and*
741 *chemotherapy* 2012, **56**(2):1019-1030.
- 742 73. Owusu-Anim D, Kwon DH: **Differential role of two-component regulatory systems (*phoPQ***
743 **and *pmrAB*) in polymyxin B susceptibility of *Pseudomonas aeruginosa*.** *Advances in*
744 *microbiology* 2012, **2**(1).
- 745 74. Choi MJ, Ko KS: **Mutant prevention concentrations of colistin for *Acinetobacter baumannii*,**
746 ***Pseudomonas aeruginosa* and *Klebsiella pneumoniae* clinical isolates.** *Journal of*
747 *Antimicrobial Chemotherapy* 2014, **69**(1):275-277.
- 748 75. Saito K, Akama H, Yoshihara E, Nakae T: **Mutations affecting DNA-binding activity of the**
749 **MexR repressor of *mexR-mexA-mexB-oprM* operon expression.** *J Bacteriol* 2003,
750 **185**(20):6195-6198.
- 751 76. Vaez H, Safaei HG, Faghri J: **The emergence of multidrug-resistant clone ST664 *Pseudomonas***
752 ***aeruginosa* in a referral burn hospital, Isfahan, Iran.** *Burns Trauma* 2017, **5**:27.
- 753 77. Braz VS, Furlan JP, Fernandes AF, Stehling EG: **Mutations in *NalC* induce MexAB-OprM**
754 **overexpression resulting in high level of aztreonam resistance in environmental isolates of**
755 ***Pseudomonas aeruginosa*.** *FEMS Microbiol Lett* 2016, **363**(16).
- 756 78. Suresh M, Nithya N, Jayasree PR, Vimal KP, Manish Kumar PR: **Mutational analyses of**
757 **regulatory genes, *mexR*, *nalC*, *nalD* and *mexZ* of *mexAB-oprM* and *mexXY* operons, in efflux**
758 **pump hyperexpressing multidrug-resistant clinical isolates of *Pseudomonas aeruginosa*.**
759 *World journal of microbiology & biotechnology* 2018, **34**(6):83.
- 760 79. Yan J, Estanbouli H, Liao C, Kim W, Monk JM, Rahman R, Kamboj M, Palsson BO, Qiu W, Xavier
761 JB: **Systems-level analysis of *NalD* mutation, a recurrent driver of rapid drug resistance in**
762 **acute *Pseudomonas aeruginosa* infection.** *PLoS Comput Biol* 2019, **15**(12):e1007562.
- 763 80. Sobel ML, Neshat S, Poole K: **Mutations in *PA2491 (mexS)* promote MexT-dependent *mexEF-***
764 ***oprN* expression and multidrug resistance in a clinical strain of *Pseudomonas aeruginosa*.** *J*
765 *Bacteriol* 2005, **187**(4):1246-1253.
- 766 81. Juarez P, Broutin I, Bordi C, Plésiat P, Llanes C: **Constitutive activation of *mexT* by amino acid**
767 **substitutions results in MexEF-OprN overproduction in clinical isolates of *Pseudomonas***
768 ***aeruginosa*.** *Antimicrobial agents and chemotherapy* 2018, **62**(5).
- 769 82. Llanes C, Köhler T, Patry I, Dehecq B, van Delden C, Plésiat P: **Role of the MexEF-OprN efflux**
770 **system in low-level resistance of *Pseudomonas aeruginosa* to ciprofloxacin.** *Antimicrobial*
771 *agents and chemotherapy* 2011, **55**(12):5676-5684.

- 772 83. Guénard S, Muller C, Monlezun L, Benas P, Broutin I, Jeannot K, Plésiat P: **Multiple mutations**
773 **lead to MexXY-OprM-dependent aminoglycoside resistance in clinical strains of**
774 ***Pseudomonas aeruginosa***. *Antimicrobial agents and chemotherapy* 2014, **58**(1):221-228.
- 775 84. Chuanchuen R, Wannaprasat W, Ajariyakhajorn K, Schweizer HP: **Role of the MexXY multidrug**
776 **efflux pump in moderate aminoglycoside resistance in *Pseudomonas aeruginosa* isolates**
777 **from *Pseudomonas* mastitis**. *Microbiology and immunology* 2008, **52**(8):392-398.
- 778 85. Hocquet D, Muller A, Blanc K, Plesiat P, Talon D, Monnet DL, Bertrand X: **Relationship**
779 **between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates**
780 **of *Pseudomonas aeruginosa***. *Antimicrobial agents and chemotherapy* 2008, **52**(3):1173-1175.
- 781 86. Islam S, Jalal S, Wretling B: **Expression of the MexXY efflux pump in amikacin-resistant**
782 **isolates of *Pseudomonas aeruginosa***. *Clinical microbiology and infection : the official*
783 *publication of the European Society of Clinical Microbiology and Infectious Diseases* 2004,
784 **10**(10):877-883.
- 785 87. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: **The intrinsic resistome of**
786 ***Pseudomonas aeruginosa* to beta-lactams**. *Virulence* 2011, **2**(2):144-146.
- 787 88. Li XZ, Ma D, Livermore DM, Nikaido H: **Role of efflux pump(s) in intrinsic resistance of**
788 ***Pseudomonas aeruginosa*: active efflux as a contributing factor to beta-lactam resistance**.
789 *Antimicrobial agents and chemotherapy* 1994, **38**(8):1742-1752.
- 790 89. Poole K, Heinrichs DE, Neshat S: **Cloning and sequence analysis of an EnvCD homologue in**
791 ***Pseudomonas aeruginosa*: regulation by iron and possible involvement in the secretion of**
792 **the siderophore pyoverdine**. *Mol Microbiol* 1993, **10**(3):529-544.
- 793 90. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T: **Expression in *Escherichia coli* of a new**
794 **multidrug efflux pump, MexXY, from *Pseudomonas aeruginosa***. *Antimicrobial agents and*
795 *chemotherapy* 1999, **43**(2):415-417.
- 796 91. Poole K, Gotoh N, Tsujimoto H, Zhao Q, Wada A, Yamasaki T, Neshat S, Yamagishi J, Li XZ,
797 Nishino T: **Overexpression of the *mexC-mexD-oprJ* efflux operon in *nfxB*-type multidrug-**
798 **resistant strains of *Pseudomonas aeruginosa***. *Mol Microbiol* 1996, **21**(4):713-724.
- 799 92. Köhler T, Michéa-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechère JC: **Characterization of**
800 **MexE-MexF-OprN, a positively regulated multidrug efflux system of *Pseudomonas***
801 ***aeruginosa***. *Mol Microbiol* 1997, **23**(2):345-354.
- 802 93. Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, Sloots TP: **Identification of**
803 ***Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction assay targeting**
804 **the *ecfX* and the *gyrB* genes**. *Diagn Microbiol Infect Dis* 2009, **63**(2):127-131.
- 805 94. Oliver A, Baquero F, Blázquez J: **The mismatch repair system (*mutS*, *mutL* and *uvrD* genes) in**
806 ***Pseudomonas aeruginosa*: molecular characterization of naturally occurring mutants**. *Mol*
807 *Microbiol* 2002, **43**(6):1641-1650.
- 808 95. van Belkum A, Soriaga LB, LaFave MC, Akella S, Veyrieras JB, Barbu EM, Shortridge D, Blanc B,
809 Hannum G, Zambardi G *et al*: **Phylogenetic distribution of CRISPR-Cas systems in antibiotic-**
810 **resistant *Pseudomonas aeruginosa***. *mBio* 2015, **6**(6):e01796-01715.
- 811 96. Buhl M, Kästle C, Geyer A, Autenrieth IB, Peter S, Willmann M: **Molecular evolution of**
812 **extensively drug-resistant (XDR) *Pseudomonas aeruginosa* strains from patients and hospital**
813 **environment in a prolonged outbreak**. *Frontiers in microbiology* 2019, **10**:1742.
- 814 97. Cabot G, López-Causapé C, Ocampo-Sosa AA, Sommer LM, Domínguez MA, Zamorano L, Juan
815 C, Tubau F, Rodríguez C, Moyà B *et al*: **Deciphering the resistome of the widespread**
816 ***Pseudomonas aeruginosa* Sequence Type 175 international high-risk clone through whole-**
817 **genome sequencing**. *Antimicrobial agents and chemotherapy* 2016, **60**(12):7415-7423.
- 818 98. **CDC & FDA Antibiotic Resistance Isolate Bank for *Pseudomonas aeruginosa*** [Available at:
819 <https://wwwn.cdc.gov/ARIsolateBank/Panel/PanelDetail?ID=12>]
- 820 99. Ramanathan B, Jindal HM, Le CF, Gudimella R, Anwar A, Razali R, Poole-Johnson J, Manikam R,
821 Sekaran SD: **Next generation sequencing reveals the antibiotic resistant variants in the**
822 **genome of *Pseudomonas aeruginosa***. *PLoS One* 2017, **12**(8):e0182524.

- 823 100. Tsang KK, Maguire F, Zubyk HL, Chou S, Edalatmand A, Wright GD, Beiko RG, McArthur AG:
824 **Identifying novel β -lactamase substrate activity through *in silico* prediction of antimicrobial**
825 **resistance.** *Microbial genomics* 2021, **7**(1).
- 826 101. Wardell SJT, Rehman A, Martin LW, Winstanley C, Patrick WM, Lamont IL: **A large-scale whole-**
827 **genome comparison shows that experimental evolution in response to antibiotics predicts**
828 **changes in naturally evolved clinical *Pseudomonas aeruginosa*.** *Antimicrobial agents and*
829 *chemotherapy* 2019, **63**(12).
- 830 102. Cortes-Lara S, Barrio-Tofiño ED, López-Causapé C, Oliver A, Gemara-Seimc Reipi Pseudomonas
831 study Group: **Predicting *Pseudomonas aeruginosa* susceptibility phenotypes from whole**
832 **genome sequence resistome analysis.** *Clinical microbiology and infection : the official*
833 *publication of the European Society of Clinical Microbiology and Infectious Diseases* 2021,
834 **27**(11):1631-1637.
- 835 103. Sun Z, Yang F, Ji J, Cao W, Liu C, Ding B, Xu X: **Dissecting the genotypic features of a**
836 **fluoroquinolone-resistant *Pseudomonas aeruginosa* ST316 sublineage causing ear infections**
837 **in Shanghai, China.** *Microbial genomics* 2023, **9**(4).
- 838 104. Su M, Satola SW, Read TD: **Genome-based prediction of bacterial antibiotic resistance.**
839 *Journal of clinical microbiology* 2019, **57**(3):e01405-01418.
- 840 105. Madden DE, McCarthy KL, Bell SC, Olagoke O, Baird T, Neill J, Ramsay KA, Kidd TJ, Stewart AG,
841 Subedi S *et al*: **Rapid fluoroquinolone resistance detection in *Pseudomonas aeruginosa* using**
842 **mismatch amplification mutation assay-based real-time PCR.** *J Med Microbiol* 2022,
843 **71**(10):001593.
- 844 106. Madden DE, Olagoke O, Baird T, Neill J, Ramsay KA, Fraser TA, Bell SC, Sarovich DS, Price EP:
845 **Express yourself: Quantitative real-time PCR assays for rapid chromosomal antimicrobial**
846 **resistance detection in *Pseudomonas aeruginosa*.** *Antimicrobial agents and chemotherapy*
847 2022, **66**(5):e0020422.
- 848 107. Mobegi FM, Cremers AJ, de Jonge MI, Bentley SD, van Hijum SA, Zomer A: **Deciphering the**
849 **distance to antibiotic resistance for the pneumococcus using genome sequencing data.** *Sci*
850 *Rep* 2017, **7**:42808.
- 851 108. Sarovich DS, Price EP: **SPANDx: a genomics pipeline for comparative analysis of large haploid**
852 **whole genome re-sequencing datasets.** *BMC research notes* 2014, **7**:618.
- 853 109. Crouch DJM, Bodmer WF: **Polygenic inheritance, GWAS, polygenic risk scores, and the search**
854 **for functional variants.** *Proc Natl Acad Sci U S A* 2020, **117**(32):18924-18933.
- 855 110. **ARDaP - Antimicrobial Resistance Detection and Prediction.**
856 [\[https://github.com/dsarov/ARDaP\]](https://github.com/dsarov/ARDaP)
- 857 111. Sherry NL, Horan KA, Ballard SA, Gonçaves da Silva A, Gorrie CL, Schultz MB, Stevens K,
858 Valcanis M, Sait ML, Stinear TP *et al*: **An ISO-certified genomics workflow for identification**
859 **and surveillance of antimicrobial resistance.** *Nat Commun* 2023, **14**(1):60.
- 860 112. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, Tyson GH, Zhao S, Hsu CH,
861 McDermott PF *et al*: **Validating the AMRFinder tool and resistance gene database by using**
862 **antimicrobial resistance genotype-phenotype correlations in a collection of isolates.**
863 *Antimicrobial agents and chemotherapy* 2019, **63**(11):e00483-00419.
- 864 113. Bekkar M, Djemaa HK, Alitouche TA: **Evaluation measures for models assessment over**
865 **imbalanced data sets.** *J Inf Eng Appl* 2013, **3**(10):27-38.
- 866 114. Hicks AL, Wheeler N, Sanchez-Buso L, Rakeman JL, Harris SR, Grad YH: **Evaluation of**
867 **parameters affecting performance and reliability of machine learning-based antibiotic**
868 **susceptibility testing from whole genome sequencing data.** *PLoS Comput Biol* 2019,
869 **15**(9):e1007349.
- 870 115. Van Goethem N, Descamps T, Devleeschauwer B, Roosens NHC, Boon NAM, Van Oyen H,
871 Robert A: **Status and potential of bacterial genomics for public health practice: a scoping**
872 **review.** *Implement Sci* 2019, **14**(1):79.
- 873 116. Kidd TJ, Ritchie SR, Ramsay KA, Grimwood K, Bell SC, Rainey PB: ***Pseudomonas aeruginosa***
874 **exhibits frequent recombination, but only a limited association between genotype and**
875 **ecological setting.** *PLoS One* 2012, **7**(9):e44199.

- 876 117. Matuschek E, Ahman J, Webster C, Kahlmeter G: **Antimicrobial susceptibility testing of**
877 **colistin - evaluation of seven commercial MIC products against standard broth microdilution**
878 **for *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter***
879 **spp.** *Clinical microbiology and infection : the official publication of the European Society of*
880 *Clinical Microbiology and Infectious Diseases* 2018, **24**(8):865-870.
- 881 118. Bassetti M, Vena A, Croxatto A, Righi E, Guery B: **How to manage *Pseudomonas aeruginosa***
882 **infections.** *Drugs Context* 2018, **7**:212527.
- 883 119. Gurjar M: **Colistin for lung infection: an update.** *J Intensive Care* 2015, **3**(1):3.
- 884 120. Sabuda DM, Laupland K, Pitout J, Dalton B, Rabin H, Louie T, Conly J: **Utilization of colistin for**
885 **treatment of multidrug-resistant *Pseudomonas aeruginosa*.** *Can J Infect Dis Med Microbiol*
886 2008, **19**(6):413-418.
- 887 121. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM: **Structure and function of OprD protein in**
888 ***Pseudomonas aeruginosa*: from antibiotic resistance to novel therapies.** *Int J Med Microbiol*
889 2012, **302**(2):63-68.
- 890 122. Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodriguez C, Moya B, Zamorano L, Suarez C,
891 Pena C, Martinez-Martinez L *et al*: **Overexpression of *AmpC* and efflux pumps in**
892 ***Pseudomonas aeruginosa* isolates from bloodstream infections: prevalence and impact on**
893 **resistance in a Spanish multicenter study.** *Antimicrobial agents and chemotherapy* 2011,
894 **55**(5):1906-1911.
- 895 123. Lee JY, Ko KS: **OprD mutations and inactivation, expression of efflux pumps and AmpC, and**
896 **metallo- β -lactamases in carbapenem-resistant *Pseudomonas aeruginosa* isolates from South**
897 **Korea.** *International journal of antimicrobial agents* 2012, **40**(2):168-172.
- 898 124. Juan C, Torrens G, González-Nicolau M, Oliver A: **Diversity and regulation of intrinsic beta-**
899 **lactamases from non-fermenting and other Gram-negative opportunistic pathogens.** *FEMS*
900 *Microbiol Rev* 2017, **41**(6):781-815.
- 901 125. Levy SB, Bonnie M: **Antibacterial resistance worldwide: Causes, challenges and responses.**
902 *Nature Medicine* 2004, **10**(12S):S122-S129.
- 903 126. Law COK, Huang C, Pan Q, Lee J, Hao Q, Chan T-F, Lo NWS, Ang IL, Koon A, Ip M *et al*: **A small**
904 **RNA transforms the multidrug resistance of *Pseudomonas aeruginosa* to drug susceptibility.**
905 *Mol Ther Nucleic Acids* 2019, **16**:218-228.
- 906 127. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC:
907 **Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside**
908 **acetyltransferase.** *Nat Med* 2006, **12**(1):83-88.
- 909 128. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler A,
910 Posch AE: **Species Identification and Antibiotic Resistance Prediction by Analysis of Whole-**
911 **Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the Unyvero Lower**
912 **Respiratory Tract Infection Trial.** *Journal of clinical microbiology* 2020, **58**(7).
- 913 129. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jänsch L, Häussler S: **Genomewide**
914 **identification of genetic determinants of antimicrobial drug resistance in *Pseudomonas***
915 ***aeruginosa*.** *Antimicrobial agents and chemotherapy* 2009, **53**(6):2522-2531.

916

917 **Tables**

918 **Table 1. Summary of antimicrobial resistance prevalence across 10 clinically relevant antibiotics in**
 919 **the *Pseudomonas aeruginosa* Global Dataset**

Antibiotic Class	Antibiotic	Res (%)	Int (%)	Sen (%)	No. isolates
Carbapenems	MEM	682 (36)	149 (8)	682 (36)	1875
	IPM	186 (29)	46 (7)	419 (64)	651
Polymyxins	CST	48 (5)	0 (0)	933 (95)	981
Fluoroquinolones	CIP	664 (54)	78 (6)	477 (39)	1219
Cephalosporins	FEP	157 (17)	111(12)	650 (71)	918
	CAZ	316 (27)	121 (10)	733 (63)	1170
Penicillins	TZP	179 (24)	52 (7)	526 (69)	757
	PIP	185 (36)	55 (11)	272 (53)	512
Aminoglycosides	TOB	294 (29)	12 (1)	695 (69)	1001
	AMK	170 (12)	56 (4)	1199 (84)	1425

920

921 Abbreviations: Res, resistant; Int, intermediate; Sen, sensitive; MEM, meropenem; IPM, imipenem;

922 CST, colistin; CIP, ciprofloxacin; FEP, cefepime; CAZ, ceftazidime, TZP, piperacillin/tazobactam; PIP,

923 piperacillin; TOB, tobramycin; AMK, amikacin

924 **Table 2. Novel antimicrobial resistance (AMR) variants identified in *Pseudomonas aeruginosa* by**
 925 **microbial genome-wide association study (mGWAS) or comparative genomic[®] analyses**

Locus	Type of mutation	Associated AMR phenotype	Fisher's Exact <i>p</i> value
PA0027	Lys34Asn	PIPr	< 0.0001
PA0091 (<i>vgrG1</i>)	Gln214His	AMKi	NA
PA0746	Lys106Asn	FEPr	< 0.0001
PA0958 (<i>oprD</i>)	Thr18fs ^{®^}	MEMr, IPMr	NA
PA0958 (<i>oprD</i>)	Phe36fs ^{®^}	MEMr, IPMr	NA
PA0958 (<i>oprD</i>)	Leu136Gln [®]	MEMr	NA
PA0958 (<i>oprD</i>)	Gly139fs ^{®^}	MEMr, IPMr	NA
PA0958 (<i>oprD</i>)	Gly193fs ^{®^}	MEMr, IPMr	NA
PA0958 (<i>oprD</i>)	Tyr199fs ^{®^}	MEMr, IPMr	NA
PA0958 (<i>oprD</i>)	Gln340Pro [®]	MEMr	NA
PA0958 (<i>oprD</i>)	Tyr350fs ^{®^}	MEMr, IPMr	NA
PA0958 (<i>oprD</i>)	Leu355fs ^{®^}	MEMr, IPMr	NA
PA0958 (<i>oprD</i>)	Leu409Pro [®]	MEMr	NA
PA1430 (<i>lasR</i>)	Glu183Gly [®]	CSTr	NA
PA1456 (<i>cheY</i>)	Val81Ala	CSTr	NA
PA1760	LOF [®]	TZPi	NA
PA1798 (<i>parS</i>)	Ala149Thr	MEMr	< 0.0001
PA1798 (<i>parS</i>)	Arg383Cys [®]	CSTr	NA
PA1798 (<i>parS</i>)	Arg7His [®]	PIPr	NA
PA1798 (<i>parS</i>)	Asp249Asn [®]	TZPr, AMKi	NA
PA1799 (<i>parR</i>)	Val68Ala	CAZr	0.0002
PA1799 (<i>parR</i>)	Leu165Phe [®]	MEMr	NA
PA1923	Ala350Val	TZPr	< 0.0001
PA1942 ¹	LOF [®]	MEMr, IPMr	NA
PA2020 (<i>mexZ</i>)	Thr32Asn [®]	MEMr	NA
PA2020 (<i>mexZ</i>)	Ser198Ile [®]	MEMr	NA
PA2020 (<i>mexZ</i>)	Leu199Arg [®]	FEPr	NA
PA2402	Val3040Ala	AMKr	< 0.0001
PA2520 (<i>czcA</i>)	Gly1051Asp [®]	CSTr	NA
PA2736	Arg30Gly	AMKr	< 0.0001
PA3047 (<i>PBP4</i> , <i>dacB</i>)	Thr27Ser	CAZr, FEPr, PIPr, TZPr	NA
PA3047 (<i>PBP4</i> , <i>dacB</i>)	Ser230Ile	CAZr, FEPr, PIPr, TZPr	NA
PA3047 (<i>PBP4</i> , <i>dacB</i>)	Phe438Leu	CAZr, FEPr, PIPr, TZPr	NA
PA3083 (<i>pepN</i>)	LOF [®]	MEMr, CAZr	NA
PA3384 (<i>phnC</i>)	LOF [®]	MEMr, TOBr	NA
PA3574 (<i>nalD</i>)	Leu76Pro [®]	MEMr	NA
PA3574 (<i>nalD</i>)	Arg164Pro [®]	PIPr, FEPr	NA
PA3721 (<i>nalC</i>)	Lys58Glu [®]	MEMr	NA
PA4020 (<i>mpl</i>)	Gly137Ser [®]	CAZr	NA

PA4109 (<i>ampR</i>)	Ter297Tyr stop lost ^{ⓂA}	PIPr	NA
PA4110 (<i>ampC</i>)	Asp272Asn [Ⓜ]	MEMr	NA
PA4110 (<i>ampC</i>) ²	Leu320Pro [Ⓜ]	MEMr	NA
PA4260 (<i>rplB</i>)	Gly138Ser [Ⓜ]	TOBi, AMKr	NA
PA4266 (<i>fusA1</i>) [#]	Ser459Phe [Ⓜ]	TOBr, AMKr	NA
PA4296 (<i>pprB</i>)	Asn253His [Ⓜ]	CSTr	NA
PA4318	Pro243Ser	PIPr	< 0.0001
PA4418 (<i>ftsI</i>)	Gly63Asp [Ⓜ]	IPMr, CAZr, FEPr, TZPr, PIPr	NA
PA4522 (<i>ampD</i>)	Val10Gly [Ⓜ]	CAZr, FEPI, PIPi	NA
PA4522 (<i>ampD</i>)	Pro41Leu [Ⓜ]	PIPr, FEPr	NA
PA4522 (<i>ampD</i>)	Glu67stop ^{ⓂA}	CAZi, MEMi, IPMi, TZPi, PIPi, FEPI	NA
PA4522 (<i>ampD</i>)	Ile69Thr [Ⓜ]	MEMr	NA
PA4522 (<i>ampD</i>)	Gln88Leu [Ⓜ]	CAZr	NA
PA4522 (<i>ampD</i>)	Gly100Glu [Ⓜ]	MEMr	NA
PA4522 (<i>ampD</i>)	Cys110Gly [Ⓜ]	FEPr	NA
PA4522 (<i>ampD</i>)	Gly116Val [Ⓜ]	MEMr, CAZr	NA
PA4522 (<i>ampD</i>)	Ile117Thr [Ⓜ]	CAZr	NA
PA4522 (<i>ampD</i>)	Gly121Glu [Ⓜ]	MEMr, CAZi	NA
PA4522 (<i>ampD</i>)	His157Tyr [Ⓜ]	CAZr	NA
PA4522 (<i>ampD</i>)	Gly169Cys [Ⓜ]	FEPr	NA
PA4599 (<i>mexC</i>)	-58C>A [Ⓜ]	FEPr	NA
PA4677	Asp138Val	FEPr	< 0.0001
PA4776 (<i>pmrA</i>)	Leu72Phe [Ⓜ]	CSTr	NA
PA4777 (<i>pmrB</i>)	Arg10Leu [Ⓜ]	CSTr	NA
PA4777 (<i>pmrB</i>)	Arg155His [Ⓜ]	CSTr	NA
PA4777 (<i>pmrB</i>)	Thr158Ile [Ⓜ]	CSTr	NA
PA4777 (<i>pmrB</i>)	Thr253Met [Ⓜ]	CSTr	NA
PA5000 (<i>wapR</i>)	Gly163Asp [Ⓜ]	CSTr	NA
PA4967 (<i>parE</i>)	Glu459Lys	CIPi	NA
PA4967 (<i>parE</i>)	Val520Ala	CIPi	NA
PA5045 (<i>ponA</i>)	Met671Ile	CAZr, FEPr, TZPr, PIPr	NA
PA5051 (<i>argS</i>)	Asp184Gly	TOBr	NA
PA5199 (<i>amgS</i>)	Trp120Gly [Ⓜ]	CSTr	NA
PA5199 (<i>amgS</i>)	Pro435Ala [Ⓜ]	CSTr	NA
PA5338 (<i>spoT</i>)	Gly496Ser [Ⓜ]	CAZr	NA
PA5493 (<i>polA</i>)	Lys395Arg [Ⓜ]	AMKr	NA

926 Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; fs,
 927 frameshift; i, intermediate resistant; IPM, imipenem; LOF, loss of function; MEM, meropenem; NA, not
 928 applicable; PIP, piperacillin; r, resistant; TOB, tobramycin; TZP, piperacillin/tazobactam

929 ¹Previously predicted to cause PIPr [129]; however, our microbial genome-wide associate study
 930 (mGWAS) analysis did not identify a significant association with this phenotype. Instead, mGWAS
 931 showed that this AMR variant was significantly associated with MEMr.


932 ²Previously identified variant in *ampC* known to reduce susceptibility to multiple cephalosporins.

933 [Ⓜ]Variant identified by comparative genomics and thus not assessed for statistical significance.

934 [#]Identified in the Validation Dataset only.

935 ^High-consequence mutations occurring in this gene are automatically identified by ARDaP.


936 **Figures**



937



938 **Figure 1. Balanced accuracy of ARDaP, abritAMR, AMRFinderPlus, and ResFinder for antimicrobial**
 939 **resistance (AMR) prediction in *Pseudomonas aeruginosa*.** Software comparisons across ten clinically
 940 relevant antibiotics were undertaken against (A) the Global Dataset ($n=1877$ isolates) and (B) the
 941 Validation Dataset ($n=102$ isolates). For both datasets, and for all 10 antibiotics, ARDaP outperformed
 942 abritAMR, AMRFinderPlus, and ResFinder. To enable comparison with existing AMR prediction
 943 software, isolates with intermediate AMR were removed prior to analysis. Abbreviations: AMK,

944 amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM,
 945 imipenem; MEM, meropenem; PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. *No
 946 strains in the Validation Dataset exhibited CST AMR; as such, balanced accuracy could not be
 947 calculated for this antibiotic.



948

949 **Figure 2. Precision and recall of ARDaP, abritAMR, AMRFinderPlus, and ResFinder across the Global**
 950 **Dataset (n=1877 strains).** Precision and recall metrics for both antimicrobial-sensitive and
 951 antimicrobial-resistant strains were highest using ARDaP (A; range 73-96%) with abritAMR (B; range
 952 54-62%), AMRFinderPlus (B; range 55-62%) and ResFinder (C; range 42-68%) all performing worse in
 953 comparison. To enable comparison with existing AMR prediction software, isolates with intermediate
 954 AMR were removed prior to analysis. Abbreviations: AMK, amikacin; CAZ, ceftazidime; CIP,
 955 ciprofloxacin; CST, colistin; FEP, cefepime; FQs, fluoroquinolones; IPM, imipenem; MEM, meropenem;
 956 PIP, piperacillin; TZP, piperacillin/tazobactam; TOB, tobramycin. N.B. Precision (resistance) is also
 957 known as positive predictive value (PPV) and precision (sensitivity) is also known as negative predictive
 958 value (NPV).



ARDaP

abritAMR

AMRFinderPlus

ResFinder

